Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Finckh

Showing results (141-150 of 225) with videos related to

Pageof 23
Sort By:
Arthritis and Rheumatism|November 1, 2006
Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban womenAxel Finckh, Glinda S Cooper, Lori B Chibnik, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 26, 2016
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial SpondyloarthritisMichael J Nissen, Adrian Ciurea, Jürg Bernhard, et al.
Annals of Internal Medicine|November 4, 2009
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysisAxel Finckh, Nick Bansback, Carlo A Marra, et al.
Current Medical Research and Opinion|October 22, 2024
Baricitinib as monotherapy for treatment of rheumatoid arthritis: analysis of real-world dataChristoper J Edwards, Tsutomu Takeuchi, Axel Finckh, et al.
Annals of the Rheumatic Diseases|April 16, 2025
Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendationsAndrea Pluma, Sabrina Hamroun, Linda Rüegg, et al.
Rheumatology (Oxford, England)|January 29, 2021
Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritisDaniel Manoil, Delphine S Courvoisier, Benoit Gilbert, et al.
Clinical Rheumatology|November 14, 2016
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)Ruediger B Mueller, Nazim Reshiti, Toni Kaegi, et al.
Rheumatology (Oxford, England)|June 23, 2026
Persistence and Effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registriesDenis Choquette, Axel Finckh, Andrea Rubbert-Roth, et al.
Journal of Clinical Medicine|July 14, 2023
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib ExperiencePeter C Taylor, Cedric Laedermann, Rieke Alten, et al.
Arthritis Research & Therapy|January 18, 2013
Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiencyPraxedis Martin, Dominique Talabot-Ayer, Christian Alexander Seemayer, et al.
Pageof 23

Showing results (141-150 of 225) with videos related to

Sort By:
Pageof 23
Arthritis and Rheumatism|November 1, 2006
Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban womenAxel Finckh, Glinda S Cooper, Lori B Chibnik, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 26, 2016
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial SpondyloarthritisMichael J Nissen, Adrian Ciurea, Jürg Bernhard, et al.
Annals of Internal Medicine|November 4, 2009
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysisAxel Finckh, Nick Bansback, Carlo A Marra, et al.
Current Medical Research and Opinion|October 22, 2024
Baricitinib as monotherapy for treatment of rheumatoid arthritis: analysis of real-world dataChristoper J Edwards, Tsutomu Takeuchi, Axel Finckh, et al.
Annals of the Rheumatic Diseases|April 16, 2025
Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendationsAndrea Pluma, Sabrina Hamroun, Linda Rüegg, et al.
Rheumatology (Oxford, England)|January 29, 2021
Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritisDaniel Manoil, Delphine S Courvoisier, Benoit Gilbert, et al.
Clinical Rheumatology|November 14, 2016
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)Ruediger B Mueller, Nazim Reshiti, Toni Kaegi, et al.
Rheumatology (Oxford, England)|June 23, 2026
Persistence and Effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registriesDenis Choquette, Axel Finckh, Andrea Rubbert-Roth, et al.
Journal of Clinical Medicine|July 14, 2023
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib ExperiencePeter C Taylor, Cedric Laedermann, Rieke Alten, et al.
Arthritis Research & Therapy|January 18, 2013
Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiencyPraxedis Martin, Dominique Talabot-Ayer, Christian Alexander Seemayer, et al.
Pageof 23